fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Chemo drug may cause significant hearing loss in longtime cancer survivors

Written by | 11 Jul 2024

An interdisciplinary study led by researchers at the University of South Florida and Indiana University has uncovered significant findings on the long-term effects of one of the most… read more.

Common blood pressure drug may make leukemia more responsive to chemotherapy while protecting heart

Written by | 1 Jul 2024

Researchers from the University of Missouri School of Medicine found that a targeted gene therapy may make acute myeloid leukemia (AML) more sensitive to chemotherapy, while also protecting the heart… read more.

Why breast cancer survivors don’t take their medication, and what can be done

Written by | 1 Sep 2023

For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they take… read more.

Experimental ovarian cancer diagnostic could lead to new precision oncology approach

Written by | 9 Aug 2023

Despite advances in surgery and chemotherapy, survival of people with certain types of ovarian cancer has not significantly changed in decades. That has meant that some ovarian cancer… read more.

European Commission approves Opdivo + chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients with tumor cell PD-L1 expression greater than 1% – BMS

Written by | 16 Jul 2023

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer… read more.

Keytruda + chemotherapy before surgery and continued as a single agent after surgery reduced the risk of event-free survival events by 42% versus pre-operative chemotherapy in resectable Stage II, IIIA or IIIB NSCLC – Merck Inc

Written by | 7 Jun 2023

Merck known as MSD outside of the United States and Canada, announced positive results from the pivotal Phase III KEYNOTE-671 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, as a… read more.

Could pharmacist-prescribing reduce chemotherapy errors?

Written by | 24 May 2023

Shannon Nally is a pharmacist with a strong background in aseptic pharmacy work and oncology. Whilst studying for a master’s degree at University College Cork (UCC) she undertook… read more.

How investment could help reduce chemotherapy prescribing errors

Written by | 23 May 2023

Chemotherapy prescribing is an “error-prone process” according to Shannon Nally, the author of a study conducted at University Hospital, Limerick. The findings suggest that prescribing of chemotherapy by… read more.

Investigating chemotherapy prescribing errors

Written by | 22 May 2023

Shannon Nally is a pharmacist with a strong background in aseptic pharmacy work and oncology. Whilst studying for a master’s degree at University College Cork (UCC) she undertook… read more.

A new method to test cancer drug toxicity

Written by | 3 May 2023

For people with cancer, chemotherapy saves lives, but for some patients, the treatment comes with a side effect—heart damage. Screening cancer drugs for cardiotoxicity has been an ongoing… read more.

Pre-surgical triple therapy shows promise for treating non-small lung cancer

Written by | 23 Mar 2023

Researchers from the NEOSTAR Phase II trial reported that the addition of ipilimumab to a neoadjuvant (pre-surgical) combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic… read more.

More proof that too many medications leads to adversity for older cancer patients

Written by | 2 Mar 2023

When older adults with cancer take multiple medications — including ordinary drugs like blood pressure pills, supplements, or antacids — it can result in more toxic chemotherapy side… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.